SAB Biotherapeutics (SABS) Q1 2024 Earnings
SABS·Reported May 20, 2024·Before market open
SAB Biotherapeutics reported Q1 2024 revenue of $944.6K. Diluted EPS came in at $-0.54, beat the $-0.98 consensus by $0.44.
Revenue
$944.6K
Diluted EPS
$-0.54beat by $0.44
Consensus: $-0.98
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about SAB Biotherapeutics's Q1 2024 earnings report.
SAB Biotherapeutics (SABS) reported Q1 2024 earnings on May 20, 2024 before market open.
SAB Biotherapeutics reported revenue of $944.6K and diluted EPS of $-0.54 for Q1 2024.
EPS beat the consensus estimate of $-0.98 by $0.44.
You can read the 10-Q periodic report (0000950170-24-062367) directly on SEC EDGAR. The filing index links above go to sec.gov.